drugset
Drugs / 4-component Meningococcal B vaccine
last change Jun 2021 re-read 3 minutes ago

4-component Meningococcal B vaccine

also known as 4CMenB

Vaccine

Developed for
infectious disease
Investigated by
Public Health England · University College, London · University of Oxford

Trials 1

today NCT02482636 · Ph 2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02482636 Aug 2015 → Nov 2017 infectious disease University of Oxford Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 4-component Meningococcal B vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02482636 ↗
Known as 4CMenB “4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months” NCT02482636 ↗
Modality Vaccine “4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months” NCT02482636 ↗
Route Intramuscular “4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months” NCT02482636 ↗